

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Raily Aesthetic Medicine International Holdings Limited**

**瑞麗醫美國際控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2135)**

### **SUPPLEMENTAL ANNOUNCEMENT TO ANNOUNCEMENT REGARDING (I) NON-FULFILLMENT OF PROFIT GUARANTEE AND (II) DISCLOSEABLE TRANSACTION DISPOSAL OF SUBSIDIARY**

Reference is made to the announcement of Raily Aesthetic Medicine International Holdings Limited (the “**Company**”) in relation to the non-fulfillment of Profit Guarantee and the Disposal dated 6 November 2024 (the “**Announcement**”). Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

The Board would like to provide shareholders and potential investors of the Company with further information.

#### **INFORMATION ON JIUMEI XINHE**

As at 31 October 2024, the unaudited consolidated book value of Jiumei Xinhe was approximately RMB3,720,740.55.

#### **FINANCIAL EFFECTS OF THE DISPOSAL AND USE OF PROCEEDS**

Upon the completion of the Disposal, Jiumei Xinhe will no longer be a subsidiary of the Company. Accordingly, the assets, liabilities and the financial results of Jiumei Xinhe will no longer be consolidated into the financial statements of the Group.

Based on (i) the Consideration of RMB3,720,000; and (ii) the unaudited consolidated book value of Jiumei Xinhe as at 31 October 2024 of approximately RMB3,720,740.55, the Group is expected to recognize an estimated net loss of approximately RMB740.55 from the Disposal.

Shareholders and potential investors of the Company should note that the above figures are for illustrative purpose only. The actual amount of gain or loss as a result of the Disposal to be recorded by the Group will be subject to the review and final audit by the auditors of the Company.

The proceeds from the Disposal are intended to be used by the Group as general working capital.

Save as stated above, all other information in the Announcement remains unchanged. This supplemental announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board  
**Raily Aesthetic Medicine International Holdings Limited**  
**Mr. Fu Haishu**  
*Chairman*

Hangzhou, the PRC, 26 November 2024

*As at the date of this announcement, the Board comprises Mr. Fu Haishu, Mr. Song Jianliang and Mr. Wang Ying as Executive Directors; and Mr. Cao Dequan, Ms. Yang Xiaofen and Mr. Liu Teng as Independent Non-executive Directors.*